A recent study done by the AARP Public Policy Institute addressed pharmaceutical giant Pfizer’s marketing tactics regarding Lipitor, a statin cholesterol medication. Having benefited from 14 years of patent protection, and massive profits, Pfizer has been looking for ways to block the generic form of its prescription drug, Lipitor, from entering the market in the face of patent expiration.
As part of its efforts to delay the release of generic Lipitor to the market, ...
continue reading...
